In patients with metastatic NSCLC, would you consider atezolizumab after failure of nivolumab or pembrolizumab?
Is there any data to support this approach? If not, are there trials you are aware of looking at "rescuing" these patients with a different checkpoint inhibitor or combination of checkpoint inhibitors?
Answer from: Medical Oncologist at Community Practice
This is an excellent unanswered question. In melanoma there is data for patients going from PD-1 or PD-L1 inhibitors to CTLA4 inhibitors or vice versa. There is no data in lung cancer patients switching between a PD-1 and PD-L1 inhibitor. Ongoing studies are looking at combination therapies followin...
Sign in or Register to read more